{"id":"W3007782584","doi":"10.1200/jco.2020.38.6_suppl.tps260","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Nuclear medicine; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003653834,0.002513448,0.003327544,0.0004289958,0.0007754922,0.001672964,0.001448082,0.002233705,0.007767765],"category_scores_gemma":[0.002413655,0.001208265,0.001638763,0.0006057887,0.00228345,0.001704289,0.0004881265,0.003740981,0.00168157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001352474,"about_ca_system_score_gemma":0.002688855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001451025,"about_ca_topic_score_gemma":0.002553375,"domain_scores_codex":[0.9986671,0.0006900087,0.00007327693,0.0002754937,0.00009153836,0.0002025438],"domain_scores_gemma":[0.9980298,0.0003658116,0.0004394678,0.0001986925,0.0001517081,0.0008145762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9717659,0.01618345,0.0006963586,0.0002043084,0.0004199311,0.00003310033,0.00005691828,0.0002081008,0.003976495,0.00006542781,0.0005714196,0.00581866],"study_design_scores_gemma":[0.8617173,0.1350092,0.001705798,0.00001106895,0.0002512788,0.00003062717,0.00002103159,0.0002566038,0.0003900004,0.00007550731,0.0005187671,0.0000127656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835719,0.001883554,0.001074863,0.0005928546,0.0005048902,0.009101658,0.001353489,0.0001577588,0.001758972],"genre_scores_gemma":[0.9743018,0.001652235,0.002994962,0.001517844,0.0007862527,0.01207666,0.002100458,0.00006988033,0.004499878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007767765,"threshold_uncertainty_score":0.02598578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08489063859828656,"score_gpt":0.4675145738132983,"score_spread":0.3826239352150118,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}